Haleon invests USD 174.2M in new Global Oral Health Hub

UK – Haleon, a global leader in consumer health and the maker of trusted brands such as Sensodyne, parodontax, Polident, Aquafresh, and Corsodyl, has broken ground on a new £130 million (USD 174.2 million) Global Oral Health Innovation Centre in Weybridge, Surrey. 

The centre will boast advanced, digitally enabled laboratories, a digital immersive room for real-time, global collaboration, and contemporary workspaces designed to foster teamwork, creativity, and commercial excellence.

Functioning as the R&D epicentre for Haleon’s oral health portfolio, the site aims to accelerate research, drive product innovation (particularly in fields such as cavity prevention and gum disease), and address the unmet needs of the estimated 3.5 billion people affected by oral health conditions worldwide.

The building’s atrium will serve as a vibrant hub where teams across scientific disciplines, supply chain, and consumer insights join forces to co-create next-generation solutions.

According to Haleon, the hub has achieved a BREEAM Outstanding rating, recognizing its exceptional sustainable design, including living roofs, a high allocation of EV charging spaces, and a focus on biodiversity.

This 90,000-square-foot facility is expected to house approximately 450 employees and play a central role in attracting and retaining scientific talent from the UK and worldwide.

Franck Riot, Chief R&D Officer, Haleon, stated, “We are excited to break ground on our Global Oral Health Innovation Centre – a major investment reflecting our commitment to advancing science and innovation.”

“This powerhouse for oral health research will strengthen Haleon’s R&D capabilities and accelerate the development of cutting-edge solutions to meet the evolving oral health needs of consumers around the world.”

This investment underscores the company’s ambition to become the foremost authority in the rapidly growing USD 20 billion global oral health market, as well as its commitment to both scientific innovation and sustainability.

Meanwhile, Haleon has completed the acquisition of the remaining 12% equity interest in TSKF, previously held by Tianjin Pharmaceutical Da Ren Tang Group, for a total consideration of CNY 1.62 billion (USD 226.8 million)

With this transaction, TSKF is now a wholly owned subsidiary of Haleon, providing the company with complete strategic and operational flexibility in China’s rapidly growing OTC market.

SKF contributed around 40% of Haleon’s China revenues in 2024.

Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.